Boston Scientific's Watchman device could soon face its first domestic competitor if Abbott's Amulet is approved by FDA in the second half as expected.

Hillrom wanted to opt-out of acquiring Bardy Diagnostics because it claimed Medicare rate cuts for long-term cardiac monitoring constituted a material adverse event to the merger agreement.

The Mountain View, CA-based company said the KardiaMobile 6L device can be used to obtain an ECG which they can use to manually measure their patients’ QTc interval.

The STAR-T trial will enroll up to 120 patients across 20 clinical sites.

The Abbott Park, IL-based company recently won approvals for its Xience family of stents in both Europe and the U.S.

The biggest medtech news of the week, in one minute or less.

Philips says its new real-time 3D intracardiac echocardiography (ICE) catheter has the potential to improve standard of care for structural heart disease and electrophysiology (EP) procedures. The device comes to market right as the EP field is...

The CE mark comes on the heels of Viz.ai raising $71 million in a series C round.

It was a big news week. Here's what you might have missed, in one minute or less.

Boston Scientific has exerted its right to acquire the remaining shares of Farapulse, a company that has developed a pulsed field ablation system for the treatment of cardiac arrhythmias.